Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
141-160 of 2,120 trials

Semaglutide for Glucose Intolerance in Women with Prior Gestational Diabetes

We are studying whether semaglutide can help women with a history of gestational diabetes manage glucose intolerance and reduce the risk of developing type 2 diabetes.

Prediabetes>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyGynecology and Obstetrics

Small Cell Lung Cancer: Niraparib with Immunotherapy

We are studying the effects of adding niraparib to immunotherapy for patients with SLFN11-positive small cell lung cancer. This research aims to see if it improves treatment after initial therapy.

Extensive Stage Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Primary IgA Nephropathy: RO7434656 Treatment Study

We are testing a new medication to see if it helps reduce protein in urine and improves kidney function in patients with Primary IgA Nephropathy at high risk of progression. The study will also evaluate safety and fatigue levels.

IgA Nephropathy>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNephrology

Pancreatic Cancer: Short vs. Long Chemotherapy

We are comparing two lengths of chemotherapy before surgery for patients with borderline and locally advanced pancreatic cancer. Our goal is to find out which duration may help improve survival rates.

Advanced Pancreatic Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesGastroenterologyOncology

Calcific Aortic Valve Stenosis: Pelacarsen (TQJ230) Study

We are studying whether the medication pelacarsen can slow the progression of calcific aortic valve stenosis in patients with high lipoprotein(a) levels. This trial will help us understand its effects compared to a placebo.

Calcific Aortic Valve Stenosis>2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Semaglutide for Reducing GI Issues in Chemotherapy Patients

We are studying whether semaglutide can help lessen gastrointestinal problems in patients undergoing high-dose chemotherapy and stem cell transplantation. The trial also looks at its safety and effects on gut health.

Mucositis and Systemic Inflammation3-6 monthsEfficacy phase (II)Standard MedicinesCost ReimbursementGastroenterologyOncology

Neuroendocrine Tumors: 177Lu-edotreotide vs. Everolimus

We are studying whether a new treatment, 177Lu-edotreotide, can help patients with neuroendocrine tumors of the lung and thymus live longer without disease progression compared to everolimus.

Neuroendocrine Tumor>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Semaglutide for Weight Loss in Low Responders After Bariatric Surgery

We are studying whether Semaglutide 2.4 mg can help individuals who haven't lost enough weight after bariatric surgery. This trial compares its effects with a placebo to see how it impacts weight loss and overall health.

Obesity1-2 yearsMonitoring phase (IV)>20 visitsStandard MedicinesDiabetologyEndocrinologyInternal Medicine

Chronic Graft-Versus-Host Disease: Axatilimab and Ruxolitinib Study

We are studying a new treatment combining axatilimab and ruxolitinib for people newly diagnosed with chronic graft-versus-host disease. The goal is to see if this combination is safe and effective in improving their condition.

Chronic Graft-Versus-Host Disease>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementAllergologyHematologyInternal Medicine

Kidney Disease: ALE.F02 Treatment Study

We are testing a new intravenous treatment, ALE.F02, for patients with rapidly progressive glomerulonephritis linked to AAV. The study aims to see if it can help protect kidney function and assess its safety.

Rapidly Progressive Glomerulonephritis6-12 monthsEfficacy phase (II)Investigational MedicinesInternal MedicineNephrology

Atopic Dermatitis: Amlitelimab Injection Study

We are evaluating the long-term safety and effectiveness of amlitelimab injections for individuals aged 12 and older with moderate to severe atopic dermatitis. This study aims to understand how the treatment impacts their symptoms and overall quality of life.

Atopic Dermatitis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Hypogammaglobulinemia: XEMBIFY Treatment Study

We are testing whether XEMBIFY, combined with standard treatment, can help prevent infections in patients with hypogammaglobulinemia linked to blood cancers. This study compares its effects to a placebo treatment.

Chronic Lymphocytic Leukaemia1-2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementHematologyInfectious DiseasesOncology

Achondroplasia: TransCon CNP Treatment

We are studying a new weekly injection for children and adolescents with achondroplasia to see if it is safe and helps improve growth. This trial will help us understand the long-term effects of this treatment.

Achondroplasia1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyPediatrics

Bladder Cancer Treatment: Chemoablation vs. Standard Care

We are studying whether a new chemoablation method is more effective than standard bladder surgery and chemotherapy for patients with recurrent non-muscle invasive bladder cancer. This may help reduce recurrence rates and improve long-term outcomes.

Recurrent Non-Muscle Invasive Bladder Cancer>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementOncologyUrology

HPV Vaccine Effectiveness Study for Young Men

We are studying how well the bivalent HPV vaccine protects men aged 19-26 who have sex with men from anal HPV-16/18 infections. This research aims to understand vaccination impact and related factors.

HPV InfectionHealthy Participants6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious Diseases

Hodgkin Lymphoma: Tislelizumab with Gemcitabine and Cisplatin

We are studying a combination of tislelizumab, gemcitabine, and cisplatin for patients with relapsed or refractory Hodgkin lymphoma. The goal is to see if this treatment improves survival and response rates.

Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Ventilator-Acquired Pneumonia: Interferon Gamma Treatment

We are studying whether recombinant human interferon gamma can help ICU patients with ventilator-acquired pneumonia breathe easier and recover faster. This trial looks at its effects alongside standard antibiotic treatment.

Ventilator-Associated PneumoniaConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicinePulmonology

Guselkumab for Children with Ulcerative Colitis

We are studying whether guselkumab can effectively treat moderately to severely active ulcerative colitis in children. This trial will help us understand its safety and how well it works over time.

Ulcerative Colitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Advanced NSCLC: Comparing Immune Treatments

We are studying two treatment strategies for patients with advanced non-small cell lung cancer to see which one works better. This trial also examines how these treatments affect the immune system and collects samples for future research.

Non-Small Cell Lung Cancer Stage IV>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPulmonology

Prostate Cancer: Metastasis-Directed Therapy Study

We are investigating if a new treatment can improve survival for men with castration-refractory prostate cancer and a few progressive lesions. This study compares the new approach to standard care to see which is more effective.

Oligoprogressive Metastatic Castration-Refractory Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology